← Back to Search

Unknown

IMB-1018972 for Hypertrophic Cardiomyopathy (IMPROVE-HCM Trial)

Phase 2

Waitlist Available

Research Sponsored by Imbria Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through week 14 safety follow-up

Awards & highlights

IMPROVE-HCM Trial Summary

This trial is testing a new drug for people with non-obstructive HCM to see if it is safe and effective.

Eligible Conditions

Hypertrophic Cardiomyopathy

IMPROVE-HCM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through week 14 safety follow-up

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through week 14 safety follow-up

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through week 14 safety follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs

Secondary outcome measures

Oxygen

IMPROVE-HCM Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: IMB-1018972 200mgExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Imbria Pharmaceuticals, Inc.Lead Sponsor

3 Previous Clinical Trials

748 Total Patients Enrolled

Paul Chamberlin, MDStudy DirectorImbria Pharmaceuticals, Inc.

6 Previous Clinical Trials

1,887 Total Patients Enrolled

Medical MonitorStudy ChairImbria Pharmaceuticals, Inc.

1,649 Previous Clinical Trials

979,658 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for individuals to partake in this investigation?

"Affirmative. According to clinicaltrials.gov, the trial that was initial posted on June 14th 2021 is still actively recruiting patients. 12 medical sites need to fill 60 slots for this study."

Answered by AI

Can octogenarians participate in this inquiry?

"Based on the trial's qualifications, any patient aged 18 or older but younger than 80 are eligible to enroll."

Answered by AI

Are there any North American medical facilities conducting this trial presently?

"This research is presently occurring across 12 facilities, including those in Los Angeles, Houston and Salt Lake City. To reduce the amount of travelling required for involvement, it is encouraged to select the closest available clinic."

Answered by AI

How many volunteers are involved in this experimental endeavor?

"Affirmative. The clinical trial is currently recruiting patients, as indicated by the data hosted on clinicaltrials.gov. This experiment was originally posted on June 14th 2021 and last updated October 11th 2022; it seeks to enrol 60 individuals across 12 sites."

Answered by AI

How can I take part in this clinical investigation?

"Qualifying individuals must have hypertrophy and be between 18 to 80 years old. At present, the medical trial is actively seeking 60 applicants."

Answered by AI

Is IMB-1018972 considered a safe therapeutic option for patients?

"The safety of IMB-1018972 is believed to be a 2 as this Phase 2 trial has clinical evidence backing its security, though there is no data that indicates how effective it may be."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

2021. "A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04826185.

All > Hypertrophic Cardiomyopathy